Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system. Effector T helper cells, mainly Th1 and Th17, cytotoxic T-cells, B-cells, macrophages, microglia, and the cytokines they secrete, are implicated in the initiation and maintenance of a deregulated immune...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2015-01-01
|
| Series: | PLoS ONE |
| Online Access: | http://europepmc.org/articles/PMC4552669?pdf=render |
| _version_ | 1811273269348663296 |
|---|---|
| author | Athanasia Mouzaki Maria Rodi Nikolaos Dimisianos Andreas Emmanuil Dimitra Kalavrizioti Rosa Lagoudaki Nikolaos C Grigoriadis Panagiotis Papathanasopoulos |
| author_facet | Athanasia Mouzaki Maria Rodi Nikolaos Dimisianos Andreas Emmanuil Dimitra Kalavrizioti Rosa Lagoudaki Nikolaos C Grigoriadis Panagiotis Papathanasopoulos |
| author_sort | Athanasia Mouzaki |
| collection | DOAJ |
| description | Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system. Effector T helper cells, mainly Th1 and Th17, cytotoxic T-cells, B-cells, macrophages, microglia, and the cytokines they secrete, are implicated in the initiation and maintenance of a deregulated immune response to myelin antigens and the ensuing immune-mediated demyelination. In this study, we investigated whether signature cytokines exist in MS patients at presentation to gain an insight into the underlying immunopathogenic processes at the early stage of the disease.We collected serum and cerebrospinal fluid (CSF) samples from 123 patients at presentation, eventually diagnosed with MS or non-inflammatory (NIND) or inflammatory neurological diseases (IND) or symptomatic controls (SC). The levels of cytokines IFN-γ, TNF-α, TGF-β1, IL-2, IL-4, IL-6, IL-10 and IL-17 were measured, and cytokine ratios, such as Th1/Th2, Th1/Th17, and Type-1/Type-2, were calculated. All parameters were tested for their correlations with the intrathecal IgG synthesis.Cytokine levels in CSF were lower than in serum in all the patients, with the exception of IL-6. Serum or CSF cytokine levels of MS patients did not differ significantly from NIND or SC, with the exception of serum IFN-γ and TNF-α that were significantly higher in NIND. IND patients presented with the highest levels of all cytokines in serum and CSF, with the exception of serum IL-10 and CSF IL-17. MS patients had a significantly lower serum Th1/Th2 ratio compared to the NIND and IND groups, and significantly lower serum Type-1/Type-2, IFN-γ/IL-10 and CSF Th1/Th17 ratios compared to IND patients. MS patients had a significantly higher CSF IL-17/IL-10 ratio compared to IND patients. The IgG index was higher in MS patients compared to the control groups; the differences reached statistical significance between the MS and the NIND and SC groups. Reiber-Felgenhauer analysis of the QIgG and QAlb indices revealed higher intrathecal IgG synthesis in MS patients, and higher blood-CSF barrier dysfunction in IND patients. The IgG index correlated with CSF IL-4 in MS patients only.We found no signature cytokines or profiles thereof in MS patients at presentation. Only IND patients presented with a clear Th1 cytokine polarization in serum and CSF. The parameters that distinguished MS patients from patients with other neurological disorders were IgG intrathecal synthesis, the IgG index and its correlation with CSF IL-4 levels. |
| first_indexed | 2024-04-12T22:56:06Z |
| format | Article |
| id | doaj.art-bcb94950b51d4689850abf56dc964bd9 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-12T22:56:06Z |
| publishDate | 2015-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-bcb94950b51d4689850abf56dc964bd92022-12-22T03:13:11ZengPublic Library of Science (PLoS)PLoS ONE1932-62032015-01-01108e013543410.1371/journal.pone.0135434Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.Athanasia MouzakiMaria RodiNikolaos DimisianosAndreas EmmanuilDimitra KalavriziotiRosa LagoudakiNikolaos C GrigoriadisPanagiotis PapathanasopoulosMultiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system. Effector T helper cells, mainly Th1 and Th17, cytotoxic T-cells, B-cells, macrophages, microglia, and the cytokines they secrete, are implicated in the initiation and maintenance of a deregulated immune response to myelin antigens and the ensuing immune-mediated demyelination. In this study, we investigated whether signature cytokines exist in MS patients at presentation to gain an insight into the underlying immunopathogenic processes at the early stage of the disease.We collected serum and cerebrospinal fluid (CSF) samples from 123 patients at presentation, eventually diagnosed with MS or non-inflammatory (NIND) or inflammatory neurological diseases (IND) or symptomatic controls (SC). The levels of cytokines IFN-γ, TNF-α, TGF-β1, IL-2, IL-4, IL-6, IL-10 and IL-17 were measured, and cytokine ratios, such as Th1/Th2, Th1/Th17, and Type-1/Type-2, were calculated. All parameters were tested for their correlations with the intrathecal IgG synthesis.Cytokine levels in CSF were lower than in serum in all the patients, with the exception of IL-6. Serum or CSF cytokine levels of MS patients did not differ significantly from NIND or SC, with the exception of serum IFN-γ and TNF-α that were significantly higher in NIND. IND patients presented with the highest levels of all cytokines in serum and CSF, with the exception of serum IL-10 and CSF IL-17. MS patients had a significantly lower serum Th1/Th2 ratio compared to the NIND and IND groups, and significantly lower serum Type-1/Type-2, IFN-γ/IL-10 and CSF Th1/Th17 ratios compared to IND patients. MS patients had a significantly higher CSF IL-17/IL-10 ratio compared to IND patients. The IgG index was higher in MS patients compared to the control groups; the differences reached statistical significance between the MS and the NIND and SC groups. Reiber-Felgenhauer analysis of the QIgG and QAlb indices revealed higher intrathecal IgG synthesis in MS patients, and higher blood-CSF barrier dysfunction in IND patients. The IgG index correlated with CSF IL-4 in MS patients only.We found no signature cytokines or profiles thereof in MS patients at presentation. Only IND patients presented with a clear Th1 cytokine polarization in serum and CSF. The parameters that distinguished MS patients from patients with other neurological disorders were IgG intrathecal synthesis, the IgG index and its correlation with CSF IL-4 levels.http://europepmc.org/articles/PMC4552669?pdf=render |
| spellingShingle | Athanasia Mouzaki Maria Rodi Nikolaos Dimisianos Andreas Emmanuil Dimitra Kalavrizioti Rosa Lagoudaki Nikolaos C Grigoriadis Panagiotis Papathanasopoulos Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation. PLoS ONE |
| title | Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation. |
| title_full | Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation. |
| title_fullStr | Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation. |
| title_full_unstemmed | Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation. |
| title_short | Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation. |
| title_sort | immune parameters that distinguish multiple sclerosis patients from patients with other neurological disorders at presentation |
| url | http://europepmc.org/articles/PMC4552669?pdf=render |
| work_keys_str_mv | AT athanasiamouzaki immuneparametersthatdistinguishmultiplesclerosispatientsfrompatientswithotherneurologicaldisordersatpresentation AT mariarodi immuneparametersthatdistinguishmultiplesclerosispatientsfrompatientswithotherneurologicaldisordersatpresentation AT nikolaosdimisianos immuneparametersthatdistinguishmultiplesclerosispatientsfrompatientswithotherneurologicaldisordersatpresentation AT andreasemmanuil immuneparametersthatdistinguishmultiplesclerosispatientsfrompatientswithotherneurologicaldisordersatpresentation AT dimitrakalavrizioti immuneparametersthatdistinguishmultiplesclerosispatientsfrompatientswithotherneurologicaldisordersatpresentation AT rosalagoudaki immuneparametersthatdistinguishmultiplesclerosispatientsfrompatientswithotherneurologicaldisordersatpresentation AT nikolaoscgrigoriadis immuneparametersthatdistinguishmultiplesclerosispatientsfrompatientswithotherneurologicaldisordersatpresentation AT panagiotispapathanasopoulos immuneparametersthatdistinguishmultiplesclerosispatientsfrompatientswithotherneurologicaldisordersatpresentation |